# Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium
Canonical URL: https://biopharmsignal.com/news/KPRX/kiora-pharmaceuticals-to-participate-in-piper-sandler-virtual-ophthalmology-symp-a9cd7ac0
Ticker: KPRX
Company: Kiora Pharmaceuticals
Source: Kiora Pharmaceuticals
Published: 2026-07-02 11:00 EST
Original Source URL: https://ir.kiorapharma.com/news-events/news-releases/detail/251/kiora-pharmaceuticals-to-participate-in-piper-sandler-virtual-ophthalmology-symposium
## Summary

Encinitas, California--(Newsfile Corp. - July 2, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that it will participate in…...

## Article Body
Encinitas, California--(Newsfile Corp. - July 2, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that it will participate in an investor fireside chat at the Piper Sandler Virtual Ophthalmology Symposium.

Presentation Details

Date: Thursday, July 9, 2026

Time: 2:30 p.m. Eastern Daylight Time

Live Presentation: Available on Kiora's Investor Relations homepage at ir.kiorapharma.com

Replay: Available for 90 days on Kiora's Investor Relations Events page at ir.kiorapharma.com/news-events/events

About Kiora Pharmaceuticals

Kiora Pharmaceuticals is a clinical-stage biotechnology company developing advanced therapies for retinal disease. We target critical pathways underlying retinal diseases using innovative small molecules to slow, stop, or restore vision loss. KIO-301 is being developed initially for the treatment of retinitis pigmentosa, with potential to expand into choroideremia and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of macular edema due to retinal inflammation. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH).

In addition to news releases and SEC filings, we expect to post information on our website, www.kiorapharma.com , and social media accounts that could be relevant to investors. We encourage investors to follow us on X and LinkedIn as well as to visit our website and/or subscribe to email alerts.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/303675

SOURCE Kiora Pharmaceuticals, Inc.

Released July 2, 2026
## Recent Company News
- 2026-07-02 11:00 EST — [Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium](https://biopharmsignal.com/news/KPRX/kiora-pharmaceuticals-to-participate-in-piper-sandler-virtual-ophthalmology-symp-a9cd7ac0) — Source: Kiora Pharmaceuticals
- 2026-06-25 13:46 EST — [Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model](https://biopharmsignal.com/news/KPRX/kiora-pharmaceuticals-reports-its-ion-channel-modulator-kio-300-suppressed-seizure-activity-in-preclinical-epilepsy-model) — Source: Kiora Pharmaceuticals
- 2026-06-25 13:46 EST — [Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/KPRX/kiora-pharmaceuticals-reports-first-quarter-2026-financial-results-and-provides-corporate-update) — Source: Kiora Pharmaceuticals
- 2026-06-25 13:46 EST — [Kiora Pharmaceuticals to Participate in the 2025 Maxim Growth Summit and Eyecelerator @ AAO 2025](https://biopharmsignal.com/news/KPRX/kiora-pharmaceuticals-to-participate-in-the-2025-maxim-growth-summit-and-eyecelerator-at-aao-2025) — Source: Kiora Pharmaceuticals
- 2026-06-25 13:46 EST — [Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular Disorders](https://biopharmsignal.com/news/KPRX/kiora-pharmaceuticals-joins-rare-x-vision-consortium-promoting-collaboration-and-development-of-new-treatments-for-rare-ocular-disorders) — Source: Kiora Pharmaceuticals
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)